| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-04-28 | PROTEVIH consortium : Innavirvax (France), Diaxonhit, INSERM-Université Paris-Sud/CESP / U1018 at Hôpital Kremlin Bicêtre, INSERM-Université de Bordeaux Segalen / ISPED - UMR 897 | €9.4 million | subsidies and refundable advance payments | Bpifrance (France) | Infectious diseases | Subvention |
| 2014-04-28 | Orca Pharmaceuticals (UK) | $1.3 million | financing round | BioMotiv (USA - OH) | Autoimmune diseases | Financing round |
| 2014-04-25 | Genalice (The Netherlands) | undisclosed | Redbrae (UK-USA) | Fundraising | ||
| 2014-04-24 | Isarna Therapeutics (Germany) | € 5.5 million | financing round | AT NewTec (Germany), Global Asset Funds (Germany), MIG Fonds (Germany) | Cancer - Oncology | Financing round |
| 2014-04-22 | Pharming (The Netherlands) | €14.7 million | private placement | existing institutional investors | Rare diseases - Genetic diseases | Private placement |
| 2014-04-22 | Hoopika Biotech (Austria) | € 1.64 million + € 3.38 million | grant | Austrian Research Promotion Agency (FFG) (Austria) | Cancer - Oncology - Infectious diseases | Grant |
| 2014-04-17 | Oncobiologics (USA - NJ) | $ 10 million | private placement | Private placement | ||
| 2014-04-16 | OxThera (Sweden) | 70 MSEK (€7.7 million) | financing round | Kurma Partners (France) IdInvest Partners (France) Mayo Clinic (USA) | Rare diseases - Kidney diseases - Renal diseases | Financing round |
| 2014-04-15 | Mucosis (The Netherlands) | € 5 million | financing round | Changchun BCHT Biotechnology Co (China), BioGeneration Ventures (The Netherlands), MedSciences Capital (The Netherlands), NV NOM (Investment and Development Agency for the Northern Netherlands) (The Netherlands), Utrecht Holdings (The Netherlands) | Infectious diseases - Respiratory diseases | Financing round |
| 2014-04-15 | Medgenics (USA - Israel) | $2.2 Million (€1.6 million) | grant | Office of the Chief Scientist (OCS -Israel) | Rare diseases | Grant |
| 2014-04-15 | AAVLife (France) | $ 12 million (€ 8.68 million) | series A financing round | Versant Ventures (USA) Inserm Transfert Initiative (France) | Rare diseases - Neurodegenerative diseases | Series A financing round |
| 2014-04-14 | Domain Therapeutics (France) | $ 230 000 (€166 110) | grant | The Michael J. Fox Foundation - MJFF (USA) | Neurodegenerative diseases | Grant |
| 2014-04-14 | The EFFIMAB consortium (Effimune, PX’Therapeutics, The Nantes Centre for Research in Transplantation and Immunology (CRTI/INSERM UMR 1064) and the Institute for Transplantation-Urology-Nephrology (ITUN), based in Nantes, the University Institute of Hematology (INSERM-UMR944) of the St Louis Hospital in Paris, the Paris Public Welfare Hospital (Assistance Publique–Hôpitaux de Paris), and the Lille Regional University Hospital Centre (CHRU de Lille) | €9.5 million | subvention and refundable aids | Bpifrance (France) | Autoimmune diseases – Inflammatory diseases - Cancer - Oncology | Grant |
| 2014-04-14 | BloodPharma consortium (the Scottish National Blood Service (UK), Cell Therapy Catapult (UK), NHS Blood and Transplant (UK), Roslin Cells (UK)) | £5 million (€ 6.04 million) | grant | Wellcome Trust (UK) | Grant | |
| 2014-04-11 | TxCell (France) | €16.2 million | IPO | Auriga Partners (France) Seventure Partners (France) Bpifrance (France) | Autoimmune diseases – Inflammatory diseases | IPO |
| 2014-04-10 | Nucana (UK) | $ 57 million (€41 million) | series B financing round | Sofinnova Venture (USA) - Sofinnova Partners (France) - Morningside Ventures (China - USA) - Alida Capital International (UK) - Scottish Investment Bank (UK) | Cancer - Oncology | Series B financing round |
| 2014-04-09 | Quantum Genomics (France) | €3.4 million | private placement | Thétys (France) and other institutional investors | Cardiovascular diseases | Private placement |
| 2014-04-08 | Biotec Pharmacon (Norway) | NOK 78 million (€9.47 million) | private placement | Medical devices | Private placement | |
| 2014-04-08 | Piqur Therapeutics (Switzerland) | CHF 32 million (€ 26.2 million) | series A financing round | Versant Ventures (USA) | Cancer - Oncology | Series A financing round |
| 2014-04-07 | Newron Pharmaceuticals (Italy) | CHF18.6 million (€15.2 million) | private placement | undisclosed institutional shareholders institutional investors joining from Europe and the USA, including J.P. Morgan Asset Management (USA), Aviva (UK), Investor AB (Sweden) and Swisscanto (Switzerland). | CNS diseases - Neurodegenerative diseases - Rare diseases | Private placement |
